VANCOUVER, British Columbia, February 27, 2018 /PRNewswire/ —
Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE: ATT) (CSE: ATT.CN) (OTC: ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Definitive Agreement”) to acquire (the…
